TB-500: Benefits, Dosage, the BPC-157 Stack, and How to Get It in 2026
Medically reviewed by the Rite Aid Health Team · Last updated June 16, 2026
TB-500 is a synthetic fragment of Thymosin Beta-4, a protein the body produces naturally. In animal research it promotes cell migration, soft-tissue and muscle regeneration, and new blood-vessel formation — which is why it is most-used for injury recovery and most often run alongside BPC-157.
It is one of the twelve peptides the FDA removed from the list that restricted compounding in April 2026, and one of seven under formal advisory review on July 23–24, 2026. If you're deciding between TB-500, BPC-157, and other recovery peptides, start with our peptide therapy guide.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
What is TB-500?
TB-500 is a synthetic peptide based on a fragment of Thymosin Beta-4 (TB-4), a naturally occurring protein found in nearly all human and animal cells.
TB-4 plays a central role in building and recycling actin, one of the structural proteins cells use to move and rebuild tissue. TB-500 reproduces the active region of that protein in a more stable synthetic form. It does not occur in this isolated form in nature.
Benefits and uses
What the research shows — most of it in animal models, which is the honest framing for TB-500:
- Soft-tissue and muscle regeneration. The most-studied effect. TB-500 promotes cell migration and the actin regulation that lets tissue rebuild, which speeds recovery in animal injury models.
- Blood-vessel formation. It supports angiogenesis — the growth of new blood vessels into healing tissue — improving the blood supply an injury needs to repair.
- Inflammation modulation. TB-500 dampens inflammatory signaling, part of why it is used during recovery.
- Systemic reach. Because Thymosin Beta-4 is present throughout the body, TB-500 is studied for whole-body cell migration and regeneration rather than purely local repair.
The gap between the volume of anecdote and the volume of human evidence is real. TB-500 has a following built on animal research and athlete reports; rigorous human clinical trials are limited. State that plainly rather than overselling.
How it works
TB-500 works largely by regulating actin, the protein that drives cell movement. By promoting cell migration to the site of an injury, it helps the cells that rebuild tissue reach where they are needed.
It also supports angiogenesis and modulates inflammation. The combined effect is faster, better-supplied tissue repair across muscle, tendon, and other soft tissue.
Dosage and administration
Typical protocols in the literature and clinical practice use subcutaneous injection, often run in a loading-then-maintenance pattern: a higher loading dose over the first 4–6 weeks, then a lower maintenance dose.
These are not official dosing guidelines — there is no FDA-approved TB-500 product — and dosing should be set by the prescribing provider.
Reconstitution (mixing the lyophilized powder with bacteriostatic water) and drawing the right volume on an insulin syringe is where most people make errors.
Use the peptide dosage calculator to convert your target dose into syringe units for your vial size.
Side effects and safety
TB-500 has shown a favorable safety profile in animal studies. Reported effects in human use are generally mild — injection-site reactions, fatigue, head rush or lightheadedness shortly after a dose.
The honest caveat: long-term human safety data does not exist. Anyone using TB-500 should monitor liver enzymes and kidney function and work with a provider.
Legal status and how to get it in 2026
This is the question most searchers actually have. The status changed this year:
- For several years TB-500 sat on the FDA's Section 503A Category 2 list, which effectively blocked compounding pharmacies from preparing it.
- On April 15, 2026 the FDA removed TB-500 (and 11 other peptides) from that Category 2 list.
- A Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026 will evaluate whether TB-500 should be formally added to the authorized bulk-substances list compounding pharmacies can use.
Until that process completes, the cleanest legal route is a prescription filled by a licensed compounding pharmacy. Products sold online "for research use only" are not manufactured or quality-controlled for human use, and buying them carries both quality and legal risk.
Rite Aid is preparing compounded peptide consultations. Join the waitlist to claim 20% off your first TB-500 order when consultations and ordering open.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
TB-500 vs BPC-157 — and why they're stacked
TB-500 and BPC-157 are the most common recovery pairing. The two do different jobs: BPC-157 drives local repair and angiogenesis at the injury site, while TB-500 supports systemic cell migration and broader soft-tissue regeneration.
Run together, they cover both the local and the whole-body side of healing, which is why they are run as a cycle rather than alone.
For the broader recovery protocol, compare TB-500 with other healing and recovery peptides, and see KPV for the anti-inflammatory addition.
Blood work to track TB-500
TB-500 doesn't have a single direct biomarker, so tracking focuses on the inflammation it's meant to reduce and on safety:
- hs-CRP — a sensitive inflammation marker; useful to see whether systemic inflammation is trending down.
- Comprehensive metabolic profile — liver enzymes and kidney function, the safety baseline for any peptide cycle.
Test before you start and again at 4–6 weeks.
Baseline tests before a peptide cycle
Check safety and response markers before starting. These tests help establish a baseline for liver, kidney, glucose, hormone, and recovery tracking.
FAQ
Most commonly for soft-tissue and muscle injury recovery — promoting cell migration, regeneration, and blood-vessel formation. The strongest evidence is in animal research; human clinical data is limited.
The FDA removed TB-500 from the Category 2 list that restricted compounding in April 2026, and a July 2026 advisory meeting will review formal authorization. A prescription filled by a licensed compounding pharmacy is the cleanest legal route. "Research use only" products are not approved for human use.
Protocols commonly use subcutaneous injection in a loading-then-maintenance pattern over 4–6 week blocks, but there is no FDA-approved product or official dosing. Dosing should be set by a prescribing provider.
Reported effects are generally mild — injection-site reactions, fatigue, lightheadedness after a dose. Long-term human safety data does not exist, which is the main caution.
Yes — it's the standard recovery pairing. BPC-157 drives local repair and angiogenesis at the injury site; TB-500 supports systemic cell migration and broader tissue regeneration.
Protocols typically run in 4–6 week blocks. For an acute injury, users often report effects within the first cycle, and inflammatory markers like hs-CRP may shift within the first few weeks.